Skip to main content

DeltaDot Partners with Qatar in Proteomics Center

NEW YORK (GenomeWeb News) – DeltaDot will partner with the Qatar Science and Technology Park to open a proteomics research and testing services lab in Doha, the London-based company said on Monday.

Under the plan, QSTP will contribute $15 million to the partnership, while DeltaDot will provide staff, expertise, and it will grant QSTP an exclusive regional license to its technology.

Projects already in the works include biomarker studies for breast cancer and colorectal cancer and the metallic content of proteins, the company said.

The center will use DeltaDot's Label Free Intrinsic Imaging technology to develop new proteomics tools. The agreement also enables DeltaDot QSTP to market DeltaDot's products in the Middle East and North Africa region.

Eulian Roberts, who is managing director of QSTP, said in a statement that the agreement fits with Qatar's plans to become a center of scientific research by 2030.

DeltaDot CEO Paul James said in a statement that the venture will help the company develop its technology and applications and expand its life sciences offerings, and that the center will serve as "a core facility to attract new ventures to the region."

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.